Disposition of 2341 shares by Richard Pulik of Roivant Sciences at 10.8 subject to Rule 16b-3
| ROIV Stock | USD 10.87 0.10 0.91% |
Slightly above 62% of Roivant Sciences' investor base is looking to short. The analysis of overall sentiment of trading Roivant Sciences stock suggests that many investors are alarmed at this time. Roivant Sciences' investing sentiment can be driven by a variety of factors including economic data, Roivant Sciences' earnings reports, geopolitical events, and overall market trends.
Roivant |
Filed transaction by Roivant Sciences Officer: Cfo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at news.google.com
 |
Roivant Sciences Fundamental Analysis
We analyze Roivant Sciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Roivant Sciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Roivant Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Roivant Sciences is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Roivant Sciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Roivant Sciences stock to make a market-neutral strategy. Peer analysis of Roivant Sciences could also be used in its relative valuation, which is a method of valuing Roivant Sciences by comparing valuation metrics with similar companies.
Peers
Roivant Sciences Related Equities
| SNDX | Syndax Pharmaceuticals | 7.99 | ||||
| LYRA | Lyra Therapeutics | 5.56 | ||||
| DAWN | Day One | 2.37 | ||||
| CGEM | Cullinan Oncology | 0.49 | ||||
| APLS | Apellis Pharmaceuticals | 0.56 | ||||
| BPMC | Blueprint Medicines | 0.68 | ||||
| KRYS | Krystal Biotech | 0.85 | ||||
| INZY | Inozyme Pharma | 1.32 | ||||
| RVMD | Revolution Medicines | 1.54 | ||||
| ASND | Ascendis Pharma | 3.39 | ||||
| VRDN | Viridian Therapeutics | 3.79 | ||||
| AKRO | Akero Therapeutics | 4.53 | ||||
| PLRX | Pliant Therapeutics | 4.78 | ||||
| PHAT | Phathom Pharmaceuticals | 6.94 |
Additional Tools for Roivant Stock Analysis
When running Roivant Sciences' price analysis, check to measure Roivant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roivant Sciences is operating at the current time. Most of Roivant Sciences' value examination focuses on studying past and present price action to predict the probability of Roivant Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roivant Sciences' price. Additionally, you may evaluate how the addition of Roivant Sciences to your portfolios can decrease your overall portfolio volatility.